Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT01002339

Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation — 01-DMPT  

Diabetes Mellitus, Adult-Onset Clinical Trial

Official title:
Optimum Immunosuppression in Renal Transplant Recipients at High Risk of Developing New Onset Diabetes After Transplantation: A Multicenter, Prospective, Controlled and Randomized Trial.

Clinical Trial Summary

New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection and graft function. However, Tacrolimus increases 2 times the risk of NODAT as compared to CsA.

Clinical Trial Description

New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. CsA and Tacrolimus are the basis of modern immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection and graft function. However, increases 2 times the risk of NODAT as compared to CsA. Objectives: a) To compare the incidence of NODAT and glucose intolerance with 3 different regimes: Tacrolimus with rapid steroid withdrawal; Tacrolimus with steroids minimization; and CsA with steroid minimization; b) To compare acute rejection rate, renal function and graft and patient survival between different regimes; and c) to investigate the influence of different regimes on subclinical atheromatosis. A total of 210 patients will be randomized. The primary efficacy variable will be NODAT or glucose intolerance at 1 year; secondary efficacy variables will be acute rejection, renal function, and changes of carotid intima-media thickness over time. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01002339
Study type Interventional
Source Fundación Canaria Rafael Clavijo para la Investigación Biomédica
Contact
Status Terminated
Phase Phase 4
Start date February 2010
Completion date June 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT00231660 - A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin Phase 3
Active, not recruiting NCT02088658 - Technology Intensified Diabetes Education Study in African Americans N/A
Terminated NCT00231634 - A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy Phase 3
Recruiting NCT04419948 - Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM N/A
Completed NCT02650206 - Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood Phase 1
Completed NCT00231530 - A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet Phase 3
Completed NCT00231647 - A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin Phase 2
Completed NCT01109927 - Early Insulin Treatment in Patients With Latent Autoimmune Diabetes Phase 4
Completed NCT00929838 - Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM N/A
Completed NCT02128854 - Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills N/A
Terminated NCT02456051 - Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients N/A
Completed NCT00236626 - A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes Phase 2